Navigation Links
Keraderm Closes on $2.5 Million Investment from NewVa Capital Partners, LP
Date:10/24/2009

BLACKSBURG, Va., Oct. 23 /PRNewswire/ -- Keraderm Corp. announced the closing today of a $2.5 million dollar Series A investment by NewVa Capital Partners, LP. Currently starting clinical trials, the company's platform harnesses phototherapy technology to treat nail and skin infections. NewVa Capital Partners is a private equity and venture capital fund managed by Third Security, LLC and provides early stage investments in companies located or considering location in the NewVa region of southwest Virginia. This is Keraderm's first institutional investment round.

"This commitment by NewVa Capital Partners provides us with the capital and resources we need to complete our clinical trial, obtain approval for our device from the Food and Drug Administration and begin rolling out our product," says Bill Cumbie, President and CEO of Keraderm. "We're looking forward to this partnership with Third Security. Third Security really works alongside the management of their portfolio companies to create value and they have a lot of experience bringing products in the life sciences to market."

Onychomycosis, a fungal infection of the nail, is a common disorder. In the United States during the past twelve months, 2.3 million prescriptions were written to treat this disease. Current pharmaceutical therapies have limited efficacy and result in relatively high recurrence rates. In some cases, the drugs prescribed can have serious side effects. Keraderm's device, which uses bursts of pulsed light to destroy the fungal infection, has demonstrated positive results in prior clinical trials. The company is currently preparing for a pivotal trial designed to meet the requirements for approval from the U.S. Food and Drug Administration. There are no approved non-invasive, non-drug based treatments for this disease.

"We are excited to be working with Keraderm to help bring their device to market. We think they have a great approach to addressing a large market that is not well served by current treatment options," said Rob Patzig, chair of NewVa Capital Partners and Chief Investment Officer of Third Security. "We believe Keraderm's device is an effective, more convenient, and safe alternative for patients."

Keraderm represents the final investment by NewVa Capital Partners, LP, which is invested in four other companies in the biotech, life sciences, and technology sectors.

About Keraderm

Keraderm Corp., headquartered in Blacksburg Virginia, is an early stage medical device company that has developed a patented, innovative, and effective treatment for nail infections. The treatment eliminates the potential serious side effects of current medications and has shown encouraging results in preclinical and early clinical testing. The Company believes that the ability to safely and effectively treat nail infections, the low cost, and the shortened treatment time of the Keraderm light-based solution will rapidly transform this billion-dollar-plus market. For more information, visit www.keraderm.com

About NewVa Capital Partners, LP

NewVa Capital Partners, LP is a private equity/venture capital fund created to make investments in companies that are considering initiating operations in, currently operating in, or willing to relocate all or a significant portion of their business to, the NewVa region of southwestern Virginia. The fund was created in 2004 by its founding partners: Virginia Tech Foundation, Carilion Clinic and Third Security, LLC. Third Security RNR LLC is the general partner and manager of the Fund. Third Security, LLC is the manager and operator of Third Security RNR LLC. For more information, visit www.newvafund.com.

About Third Security, LLC

Third Security is an independent private equity and venture capital firm formed in 1999 to manage investments in public and private companies. Third Security evaluates opportunities in a wide range of industries, but principally focuses on emerging through late-stage investments in life sciences and information technology. For more information, visit www.thirdsecurity.com.

SOURCE Third Security, LLC


'/>"/>
SOURCE Third Security, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
2. American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008
3. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
4. Blue Belt Technologies, Inc. Closes Series A Financing
5. Curemark Closes Series A Financing
6. Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
9. BioVascular Inc. Closes $10.87 Million Series C Financing
10. AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
11. Four Pharmaceutical Companies Pay $124 Million for Submission of False Claims to Medicaid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 2016 PaperHive Will Enable ... Elsevier,s ScienceDirect Database Elsevier , ... information products and services, today announced it will ... collaboration platform PaperHive to enable researchers to easily discover, ... on ScienceDirect , the world,s largest database ...
(Date:5/31/2016)... PUNE, India , May 31, 2016 ... 2016" market research report with comparative analysis of Asthma ... mechanism of action (MoA), route of administration (RoA) and ... and press releases. It also reviews key players involved ... on late-stage and discontinued projects. Complete report ...
(Date:5/30/2016)... , May 30, 2016 On ... eliminate viral hepatitis by 2030. At the 69 th ... ever Global Viral Hepatitis Strategy, signalling the greatest global commitment ... a goal of eliminating hepatitis B and C by 2030 ... if reached, will reduce annual deaths by 65% and increase ...
Breaking Medicine Technology:
(Date:5/31/2016)... , ... May 31, 2016 , ... According to recent ... States, and more than 100,000 physical therapy clinics. Each physical therapy professional and ... of clients. At the same time, staying afloat in a competitive industry is also ...
(Date:5/31/2016)... ... , ... Throughout the day, adults often find themselves reaching for a cup of coffee, an ... be reaching for instead is a cup of Matcha green tea. Matcha is a premium ... tea is harvested from early June to mid-July, when the leaves are the most tender. ...
(Date:5/31/2016)... ... , ... Twenty years ago it was revolutionary: enabling the people who hear ... they hear. But this approach has proven transformative, both for people who hear voices ... and now is used around the world, but it still lags in the United ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... device that enables unprecedented portability and convenience. , The Cube is exceptionally small—it ... in size, the Cube fits easily into any space, whether in a hospital, ...
(Date:5/31/2016)... ... May 31, 2016 , ... WaterField Designs, an innovative ... announces the waxed-canvas and leather Duo Dopp Kit , the ideal gift upgrade ... ballistic nylon, the Duo is smartly designed for Dad’s grooming routine. Two ...
Breaking Medicine News(10 mins):